Pyxis Tankers beat estimated earnings by 5.26%, reporting an EPS of $0.2 versus an estimate of $0.19. Revenue was down $1.50 million from the same period last year. During the previous quarter, the ...

Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple ...

Pyxis Tankers (NASDAQ:PXS) is gearing up to announce its quarterly earnings on Thursday, 2026-03-05. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 ...